CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC)
暂无分享，去创建一个
A. Wyatt | L. Seymour | A. Hansen | S. Ellard | S. Hotte | C. Kollmannsberger | F. Vera-Badillo | S. Sridhar | E. Winquist | C. Canil | K. Chi | M. Cabanero | U. Emmenegger | M. Salim | M. Smoragiewicz | D. Finch | J. Gingerich | N. Iqbal | D. Tu | Aly-Khan A. Lalani